Important note

This AI stock analysis for Resmed is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Resmed - AI Stock Analysis

Analysis generated March 20, 2025

Resmed, an internationally renowned player in the health care sector, specializes in innovative respiratory care solutions. The company's product portfolio includes devices and software solutions for diagnosing, treating, and managing sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed's consistent thrust on R&D has enabled it to develop advanced products that improve patients' lives and reduce healthcare costs. Headquartered in San Diego, California, Resmed operates in over 140 countries.

Fundamental Analysis

Resmed has demonstrated robust growth metrics based on its latest financials. The revenue for the last quarter was $1.31B, marking a 4.55% increase from the preceding quarter and an 11.44% elevation from the same quarter last year. This establishes a positive growth trajectory for the company. Furthermore, the net income stood at $345M, up by 10.68% from the previous quarter and an impressive 65.05% increase year-over-year, which is a strong indication of improved profitability.

EBITDA for the latest quarter was recorded at $425M, showcasing a 7.57% rise from the prior quarter and a remarkable 49.95% increase compared to the previous year. Such figures attest to Resmed's growing operational efficiency and profitability.

However, the company’s current Price to Earnings (P/E) ratio is 25.97. While a higher P/E ratio can sometimes be a signal of expected growth, it is also a potential indicator of overvaluation and may suggest a bearish outlook.

Additionally, insider selling over the past few months could serve as a bearish signal as it might indicate low confidence among internal stakeholders.

Technical Analysis

Resmed's stock price currently stands at $222.58, a short-term concern given the 4.39% decrease from a month ago. However, in the long-term, the stock has risen by 15.92% compared to a year ago, indicating a positive long-term trend despite recent bearish momentum.

The stock's moving averages add further nuance to this analysis. The current SMA10 is 222.78, down from the previous SMA10 of 224.19, suggesting a potential downtrend in price movement. Moreover, the Relative Strength Index (RSI) of 31.9 signifies a neutral market condition but close to oversold territory, which may present a buying opportunity if the fundamentals align.

Alternative Data Analysis

Examining alternative data sources, Resmed appears poised for growth despite mixed indicators. The company has 382 open positions, a 22% increase over the past couple of months, indicative of expansion and potentially a sign of health. Employee sentiment remains neutral, providing neither a particularly bullish nor bearish signal at this moment.

Regarding digital engagement, Resmed's website attracted approximately 3.1M visitors with no significant fluctuation recently. This stable web traffic implies steady customer interest. On social media, the Instagram following surged by 21% to 6,800 followers, signaling rising interest, whereas Twitter followers remained constant at 11,000.

An AI score of 71 from AltIndex, based on a blend of fundamental, technical, and alternative data, signals a favorable outlook and considers Resmed a buy.

Conclusion

Considering the extensive data:

• Positive revenue, net income, and EBITDA growth year-over-year.
• A high P/E ratio and recent insider selling, which could warrant caution.
• The technical analysis showing a short-term bearish trend but positive long-term performance.
• Mixed but generally positive alternative data insights, particularly the increase in job postings and Instagram followers.

Given these factors, the overall recommendation is to cautiously consider Resmed for a long-term position, taking into account the company's fundamental strength and improved financial metrics. Bearish short-term technical indicators should be monitored closely for potential buying opportunities.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.